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Abstract
Aim: Viral hepatitis is one of the most important causes of chronic hepatitis. Liver biopsy is used to verify clinical 
diagnosis and to evaluate necroinflammation and fibrosis. Biopsy is the guide for therapy and can be performed also 
after treatment to assess the effect of therapy on liver. This paper aimed to explore histopathological characteristics 
of biopsy samples, which had been referred to our department with the clinical diagnosis of chronic viral hepatitis, in 
reference to Ishak Modified Hepatic Activity Index (IMHAI), as well as to compare inflammatory scores and stages in 
the groups created according to the number of portal area (PA).
Materials and Methods: The study included 107 patients that underwent liver biopsy in 2011 being diagnosed with chronic 
viral hepatitis. Age, gender and type of viral hepatitis were retrospectively reviewed and histological findings such as IMHAI 
inflammatory score and stage, hepatosteatosis and ground glass hepatocytes were re-assessed by two pathologists.
Results: Of the present cases, 97 had chronic hepatitis B, 5 had chronic hepatitis C, and 5 had chronic hepatitis BDThe 
group with PA number of 2-4 consisted of 8 cases and the group with PA number of 11 and over consisted of 37 cases.
Conclusion: Statistical analysis performed by comparing IMHAI inflammatory score and stage with PA revealed that 
score and stage were significantly higher in PA ≥ 11 groups as compared to PA 2-4 group.
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Introduction
In Turkey, viral hepatitis is the leading cause of chronic 
hepatitis.[1] Liver biopsy is the gold standard to verify clinical 
diagnosis, to assess the degree of necroinflammation and 
fibrosis as well as the course of comorbidities, and to make 
a contribution to therapy regulation.[2,3] Assessment of 
fibrosis and necroinflammatory changes such as interface 
hepatitis, portal area (PA) inflammation, intralobular focal 
lytic and confluent necrotic lesions is of great importance 
for histopathology of viral hepatitis as was for the other 
etiological factors of chronic hepatitis.[3,4]
Different scoring systems have been developed for 
necroinflammation and fibrosis. In these systems, the 
degree represents necroinflammation, whereas disease 
activity substantially determines the capacity of response 
to therapy. Although fibrosis is defined as stage, it provides 
information about disease course in the long‑term.[2,3] It has 
been reported in the literature that the number of PA should 
be at least 11 to assess stage and inflammatory score.[3] 
A PA should include connective tissue with at least two 
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embedded lumen configurations and lumens should have 
been surrounded with this tissue.[5]
The present study aimed to evaluate the adequacy of the 
number of PAs in the liver biopsy samples referred to our 
clinic for chronic viral hepatitis considering 11 PAs as the 
reference and to highlight histopathological characteristics 
of these biopsy samples.
Materials and Methods
The study included biopsies of 107 cases diagnosed with 
chronic viral hepatitis in 2011, which had been referred to 
the Pathology Department of Haseki Training and Research 
Hospital. Biopsies had been performed in the radiology 
department from the right lobe of the liver via percutaneous 
biopsy method and fixed with 10% formaldehyde. After 
routine procedures in the pathology laboratory, samples have 
been embedded into paraffin. Sections of 5 µm in thickness, 
which have been obtained by microtome, had been stained 
with histochemical stains including hematoxylin and eosin, 
reticulin, Masson’s trichrome, Periodic Acid‑Schiff (PAS), 
and Prussian blue. All preparations were re‑evaluated by 
two observers in reference to Ishak Modified Histological 
Activity Index (IMHAI) [Tables 1 and 2].[6] Inflammatory 
score was determined by the presence of periportal or 
periseptal interface hepatitis, confluent necrosis and 
portal inflammation, whereas stage was determined by the 
presence of fibrosis. Age and gender of patients, type of viral 
hepatitis, histological ground glass change, macro and micro 
vesicular steatosis, and small and large cellular changes were 
reviewed. The cases were divided into four groups according 
to the number of PAs; 2‑4, 5‑7, 8‑10, and 11 and over.
Statistical analyses were done using SPSS package program. 
T‑test was used for the comparison of two groups, whereas 
“one‑way ANOVA and Tukey‑b” test were used for the 
comparison of more than two groups.
Results
Of the 107 cases, 72 were male and 35 were female; 97 
had chronic hepatitis B (CHB), 5 had chronic hepatitis 
BD (CHBD), and 5 had chronic hepatitis C (CHC).
The mean age of the patients was 39.9 ± 1.3 years for CHB, 
37.8 ± 9.5 years for CHBD and 50.6 ± 2.1 years for CHC.
Number of cases was 8 in the PA 2‑4 group, 23 in the PA 
5‑7 group, 39 in the PA 8‑10 group and 37 in the PA 11 
and over group.
The mean number of PA was 8.1 ± 0.9 in 97 CHB cases, 
7.6 ± 1.14 in CHC cases and 7.4 ± 1.14 in CHBD cases 
[Tables 3 and 4].
No large or small cell change was detected.
Interface hepatitis was absent in 17 CHB cases and in one 
CHBD case. Of the interface hepatitis cases with a score 
of 8, eight had CHB and two had CHBD.
Table 1: Scoring of necroinflammatory activity
Periportal or periseptal interface hepatitis
Absent 0
Mild (focal, few portal areas) 1
Mild-moderate (focal, most portal areas) 2
Moderate (continuous around <50% of tracts or 
septa)
3




Zon 3 necrosis in some areas 2
Zon 3 necrosis in most areas 3
Zon 3 necrosis+occasional portal-central bridging 4
Zon 3 necrosis+multiple portal-central bridging 5
Panaciner or multiacinar necrosis 6
Focal lytic necrosis
Absent 0
One focus or less per×10 objective 1
Two to four foci per×10 objective 2
Five to ten foci per×10 objective 3
More than ten foci per×10 objective 4
Portal inflamation
Absent 0
Mild, some or all portal areas 1
Moderate, some or all portal areas 2
Moderate/marked all portal areas 3
Marked, all portal areas 4
Table 2: Ishak staging
Ishak staging
Absent 0
Fibrous expansion of some portal areas 1
Fibrous expansion of most portal areas 2
Fibrous expansion of most portal areas with occasional
Portal to portal bridging 3
Fibrous expansion of most portal areas with maked
Portal-portal and portal-central bridging 4
Marked bridging with occasional nodules (incomplete cirrhosis) 5
Cirrhosis 6














CHB 6 20 36 35 97
CHBD 1 2 1 1 5
CHC 1 1 2 1 5
CHB=Chronic hepatitis B, CHBD=Chronic hepatitis BD, CHC=Chronic 
hepatitis C
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Confluent necrosis was detected in 11 cases; of which 5 were 
focal necrosis and 6 were in the form of zone 3 necrosis in 
some areas.
Focal lytic necrosis was absent in two of CHB and one of 
CHC cases.
Portal inflammation was not detected in two cases. The score 
was 4 in five cases, 3 in 20 cases, 2 in 34 cases and 1 in 46 cases.
Steatosis was observed in the form of macrovesicular 
steatosis. Steatosis was not detected in 44 CHB cases, in 
one CHC case and in 3 of CHBD cases.
Ground glass appearance was detected in 76 CHB and 4 
CHBD cases.
With regard to stage, the score was 5 in two CHB cases, 
4 in three CHB and one CHC cases, and 3 in seven CHB 
and one CHBD cases. Cirrhosis was not observed in any of 
the cases [Figures 1‑4].
Statistical analyses performed to compare IMHAI score and 
PA revealed that inflammatory score is significantly higher 
in the PA 11 and over group as compared to the PA 2‑4 
group. No significant difference was found between PA 5‑7, 
8‑10 and PA 11 groups [Table 5].
Comparing IMHAI stage and PA, it was significantly higher 
in the PA 11 and over group than the PA 2‑4 group, whereas 
no significant difference was observed between the PA 5‑7 
and 8‑10 groups [Table 6].
Discussion
Clinical chronic hepatitis is the persistence of hepatic 
inflammation for more than 6 months without 
Table 4: The mean stage and inflammatuar score of 
viral hepatitis
IMHAI stage and 
inflammatory scoring
CHB CHBD CHC
Stage 1.19 1.2 1
Inflamatuar score 5.39 9.4 4.6
CHB=Chronic hepatitis B, CHBD=Chronic hepatitis BD, CHC=Chronic 
hepatitis C
Table 5: Inflammatory score is significantly higher in the 
PA 11 and over group as compared to the PA 2‑4 group
PA N Mean P
2-4 group 8 2.88
11 and over group 37 6.3 0
PA=Portal area
Table 6: Stage is significantly higher in the PA 11 and 
over group than the PA 2‑4 group
PA N Mean P
2-4 group 8 0.62
11 and over group 37 1.41 0.01
PA=Portal area
Figure 1: Interface hepatitis‑ focal lytic necrosis H and E, ×100
Figure 2: Graund glass apperance H and E, ×100
Figure 3:	Bridging	fibrosis,	steatosis	H	and	E,	×100
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improvement.[3,4] Its etiology includes hepatitis B viruses 
(HBV), hepatitis C viruses (HCV), and hepatitis D 
viruses, autoimmune hepatitis, α‑1‑antitripsin deficiency, 
Wilson’s disease and drug‑induced hepatotoxicity.[1,3] 
Drug‑induced hepatotoxicity results from the fact that the 
liver is the main organ for the metabolism of many drugs 
and chemical substances. However, the rate of drug‑induced 
hepatotoxicity is 10% for acute hepatitis and 1% for 
chronic hepatitis.[7] HBV and HCV involve approximately 
400‑500 million people all over the world.[8] While HBV is 
the most common cause of chronic hepatitis both in Turkey 
and worldwide, HCV is the second leading cause of chronic 
hepatitis in Turkey.[1] CHB is seen at a rate of 5‑10% in 
adults. The incidence of becoming chronic is approximately 
95% in the neonates that receive HBV infection in the 
perinatal period from an infected mother. HCV becomes 
chronic at a rate of 60‑80% in adults.[9]
HBV infection leads to acute, fulminant or chronic hepatitis, 
as well as cirrhosis and hepatocellular carcinoma (HCC). In 
the long‑term studies, incidence of cirrhosis within 5 years 
after diagnosis was 8‑20% in the patients with CHB. HCC 
is the fifth leading cancer all over the world with higher risk 
in cirrhosis patients. The incidence of hepatic carcinoma has 
been decreased along with worldwide immunization.[10] HCV 
infection is the leading cause of cirrhosis and HCC in the 
Western countries.[11] Since CHC is usually asymptomatic, 
it can be diagnosed in the late period. The incidence of 
cirrhosis due to CHC is about 20% within 20 years from 
the beginning.[10]
Liver biopsy has begun to be used as the low‑risk 
procedure in 1923 and is indicated for acute or subacute 
hepatic insufficiency, hepatic disease of unknown origin, 
post‑transplantation cellular rejection, and for the 
evaluation of inflammatory score and stage of chronic 
hepatitis. It is the gold standard for the evaluation of 
hepatic diseases.[5,12] Technically, percutaneous liver biopsy 
is used at the most. Presence of ascites and coagulopathy 
make biopsy impossible, and bleeding is the most important 
complication.[12,13] Biopsies had been performed in the 
radiology clinic of our hospital through the right hepatic 
lobe using Toshiba Aplio device with the assistance of 
3.5 MHz convex probe. A 16 G semi‑automatic needle 
had been used. Prior to the biopsy procedure, bleeding 
parameters of the patients had been evaluated and 
medications that are likely to influence bleeding had been 
discontinued 3 days before the procedure. The needle is 
able to take a sample of 22 mm in length. The shrinkage 
on the biopsy length which occurs due to formalin fixation 
shall be considered. For patients with viral hepatitis short 
specimens lead to difficulties in the diagnosis of cirrhosis 
and reduction at the score of IMHAI.[14] Although there 
is no current consensus on the number of PA and length 
of needle for the adequacy of biopsy, it has been reported 
in the literature that it should include at least 4‑6 PA.[2,5] 
Again, it has been reported that accurate evaluation of 
inflammatory score and stage requires 11‑15 PA and/or 
20 mm needle length.[6,12,13]
Histologically, a PA includes portal vein, hepatic artery 
and interlobular bile duct, which is also defined as portal 
triad. Sometimes, one of these configurations may be 
absent and then it is defined as portal dyad.[5] The number 
of patients having 2‑4 PAs in the biopsies was lower than 
the patients in other groups. This may be associated with 
statistically significant IMHAI in the other groups. However, 
considering histological significance of the procedure, it is 
possible to say that evaluation with the presence of 5 or 
more PA would be more accurate.
Scoring systems have been developed to determine 
necroinflammatory activity and fibrosis development in 
chronic hepatitis. Ishak suggested the modified histological 
activity index.[15,16] Necroinflammation indicates disease 
activity, severity and response to therapy and is defined as 
“grade”, whereas fibrosis, which indicates disease prognosis 
in the long term, is defined as “stage”.[2] IMHAI comprises 
higher number of stages as compared to other scoring 
systems.[16] In our department, IMHAI scoring system 
is being used for the evaluation of necroinflammatory 
activity and fibrosis in chronic hepatitis. As is defined in 
the literature, descriptive detail in IMHAI is beneficial 
for pathological evaluation.[6,15] Consultations performed 
in our department revealed enhanced interpersonal 
consistency. In this system, confluent necrosis is another 
category and is important in terms of indicating the severity 
of disease.[6] While, confluent necrosis involves higher 
number of hepatocytes (multiple contiguous), spotty lytic 
necrosis involves less number of hepatocytes and in the 
form of focal necrosis. Both of them indicate the severity 
of lobular inflammation.[11,15] Necrosis area including 
lymphocytes and plasma cells as well as apoptotic corpuscle 
is conspicuous in focal lytic lesions. This area also includes 
Kupffer cell hypertrophy and granular debris.[4,7] In severer 
Figure 4:	Bridging	fibrosis.	Masson	Trichrome,	×100
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cases, confluent necrosis results in bridge necrosis between 
PAs or between PA and central vein; massive hepatic 
necrosis may be developed when it becomes widespread.[3,7] 
Five of the present cases had focal and six had confluent 
necrosis in some areas in the form of zone 3 necrosis. Two 
of them had CHBD, one had CHC and remaining had 
CHB. While focal lytic lesion was absent in two CHB and 
one CHC cases, score 4 was present in one CHB and one 
CHBD cases.
Hepatitis leads to clinical and functional changes.[17] Immune 
cell reaction joins from PA in chronic viral hepatitis. Great 
majority of inflammatory cells consist of T‑lymphocytes but 
may sometimes be accompanied by plasma cells and one or 
two eosinophils.[3,17] Inflammation becomes more remarkable 
in immunoreactive period.[18] Although predominance of 
plasma cell in PA is characteristic for autoimmune hepatitis, 
it may be seen also due to CHB, certain drug‑induced 
chronic hepatitis and CHC. Lymphocytic aggregate and 
lymphoid follicles are typical, but not pathognomonic, for 
CHC.[4] Portal inflammation score was 4 in five cases, 3 in 
20 cases, 2 in 34 cases and 1 in 46 cases; whereas the score 
was ‘zero’ in two cases.
Severe hepatocyte injury occurs due to intracellular 
viral load and as the result, remarkable balloon 
degeneration (cell swelling), steatosis and cholestasis 
appear.[3] Cell death occurs via lysis and apoptosis in 
nucleus and cell membrane. Cytoplasmic density and 
eosinophilic evidence attract attention during apoptosis. 
Apoptosis is frequent, but not pathognomonic, in 
viral hepatitis.[3,4,17] Ground glass appearance occurs in 
hepatocytes due to accumulation of Hepatitis B surface 
Antigen (HbsAg) in endoplasmic reticulum.[9,11] Ground 
glass appearance may also be seen in drug‑induced 
endoplasmic reticulum hypertrophy, cyanamide toxicity 
and storage diseases.[18] Although steatotic change in 
hepatocytes is known as the characteristic of CHC, it 
may be seen in other types of chronic hepatitis and fatty 
liver disease as well. It has been reported in the literature 
that steatosis is more common in CHB as compared to 
the general population.[6,18] It is usually macrovesicular.[4] 
Hepatitis C‑related steatosis is less severe, do not show 
zonal distribution, but may be a little pericentral as is in 
fatty liver disease, and may also be seen in the mid‑zone 
or periportal area. The diagnosis should be fatty liver 
when it is much more widespread and zonal.[6] Steatosis 
was macrovesicular in the present cases. It was observed 
in 53 CHB, 2 CHBD and 4 CHC cases; however, zonal 
distribution could not be determined.
Iron storage is mildly increased in chronic viral hepatitis, 
particularly in CHC. Again, it is increased also with ribavirin 
therapy.[6] Chronic hepatitis is rarely encountered in genetic 
hemochromatosis and almost always occurs due to HCV 
and HBV infections.[4] Iron storage could not be detected 
in the present cases during histochemical staining with 
Prussian blue.
Interface hepatitis (piecemeal necrosis) is the periportal 
hepatocyte injury caused by very close portal inflammatory 
cells by passing over limiting plate. It may not be seen in 
all periportal areas but may occur in a part of, or entire, 
periportal area.[3,4,15] Bile duct proliferation and fibrosis occur 
in interface hepatitis. Collagen synthesis in the PA is caused 
by portal myofibroblasts and hepatic satellite cells. Ductal 
reaction itself is also profibrogenic.[3,11] Interface hepatitis 
was not present in 17 CHB and in one CHBD cases. Of the 
interface hepatitis case with a score of 4, eight were CHB 
and two were CHBD.
Regenerative changes occur in the hepatocytes along with 
progression in interface hepatitis and periportal fibrosis. 
Thickness of cell cords is increased up to the thickness 
of two or more cells.[3] Nucleus and nucleolus sizes of 
hepatocytes are morphologically increased and cells 
including two or three nuclei attract attention.[4,17] Large 
and small cell changes, previously known as dysplasia, have 
not been detected in the present cases. While large cell 
change indicates increased risk for HCC, small cell change 
is considered to be premalignant. In large cell change, 
hepatocytes are found in periportal and periseptal areas 
mixed with other hepatocytes, whereas they are found as 
groups in small cell change.[6]
As fibrosis progresses, bridging fibrosis occurs between the 
PAs. In time, central‑portal bridging fibrosis may occur 
in the necrosis including zone 3. Fibrosis is reversible 
and shows the low‑rate progression particularly in CHC 
patients treated with interferon. Cirrhosis is developed 
as the consequence of fibrosis.[4] Capsule and subcapsular 
region should be paid particular attention during evaluation. 
Capsule shows extensions into the parenchyma and may 
lead to bridging and nodularity even though the spectrum 
is normal.[6] Cirrhosis is the leading cause of morbidity and 
mortality in viral hepatitis.[11] Fibrosis is evaluated by using 
histochemical staining such as Masson’s trichrome and 
reticulin.[3] Evaluation of staging revealed a score of 5 in 
two CHB cases, 4 in three CHB and one CHC cases, and 
3 in seven CHB and one CHBD cases. Cirrhosis was not 
found in any of the present cases.
In this paper, a statistical evaluation was performed about 
the adequacy of liver biopsies based on the number of PAs, 
and histology of chronic viral hepatitis was highlighted 
by evaluating existing biopsies in reference to IMHAI. 
Accordingly, more than 4 portal areas are required in 
biopsies. As is reported in the literature, a PA number of 
at least 11 would provide more accurate results to avoid 
inadequate scoring.[6] Report of liver biopsies should be 
consistent with the clinic, and scoring system should be 
mentioned in detail in the report.
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